Figure 5. High FMO2 expression was sensitive to immunotherapy in PFS. (A) Anti-PD-1 immunotherapy. (B) Anti-PD-L1 immunotherapy. (C) Anti-CTLA-4 immunotherapy. (D) Pembrolizumab immunotherapy. (E) Nivolumab immunotherapy. (F) Atezolizumab immunotherapy. (G) Durvalumab immunotherapy. (H) Ipilimumab immunotherapy.